Search research articles
Contact Us
Filters
Showing results (41-50 of 69) with videos related to
Page
of 7
Sort By:
The New England Journal of Medicine
|
May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism
|
July 2, 2026
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial
Daniel Raaschou-Oddershede, Christine R Schwarz, Tanya Kovalova, et al.
Pediatric Research
|
June 21, 2022
More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes
Angelica Cristello Sarteau, Anna R Kahkoska, Jamie Crandell, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
August 7, 2021
Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial
Sun H Kim, Irwin G Brodsky, Ranee Chatterjee, et al.
Circulation
|
November 15, 2021
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Carolyn S P Lam, Chinthanie Ramasundarahettige, Kelley R H Branch, et al.
American Heart Journal
|
October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
Metabolism Open
|
August 20, 2020
Reproducibility of a prediabetes classification in a contemporary population
Chhavi Chadha, Anastassios G Pittas, Christine W Lary, et al.
JAMA Cardiology
|
October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
Darren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Diabetes Care
|
July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Peter Rossing, George Bakris, Vlado Perkovic, et al.
Circulation
|
October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 69) with videos related to
Sort By:
Page
of 7
The New England Journal of Medicine
|
May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism
|
July 2, 2026
Potential Mediators of Efpeglenatide's Cardiovascular Benefit: An Exploratory Analysis of the AMPLITUDE-O Trial
Daniel Raaschou-Oddershede, Christine R Schwarz, Tanya Kovalova, et al.
Pediatric Research
|
June 21, 2022
More hypoglycemia not associated with increasing estimated adiposity in youth with type 1 diabetes
Angelica Cristello Sarteau, Anna R Kahkoska, Jamie Crandell, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
August 7, 2021
Effect of Vitamin D Supplementation on Kidney Function in Adults with Prediabetes: A Secondary Analysis of a Randomized Trial
Sun H Kim, Irwin G Brodsky, Ranee Chatterjee, et al.
Circulation
|
November 15, 2021
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
Carolyn S P Lam, Chinthanie Ramasundarahettige, Kelley R H Branch, et al.
American Heart Journal
|
October 6, 2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Christopher P Cannon, Darren K McGuire, Richard Pratley, et al.
Metabolism Open
|
August 20, 2020
Reproducibility of a prediabetes classification in a contemporary population
Chhavi Chadha, Anastassios G Pittas, Christine W Lary, et al.
JAMA Cardiology
|
October 8, 2020
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
Darren K McGuire, Weichung J Shih, Francesco Cosentino, et al.
Diabetes Care
|
July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Peter Rossing, George Bakris, Vlado Perkovic, et al.
Circulation
|
October 7, 2020
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
Francesco Cosentino, Christopher P Cannon, David Z I Cherney, et al.
Page
of 7